Jan Stahlberg bought $6.0M of DMAC
owner at DiaMedica Therapeutics Inc.. 1,000,000 shares at an average of $5.96, traded Aug 13, 2025, filed Sep 4, 2025.
Score components
- +12Role10% owner
- +25Trade size$6.0M at market
- +3Relative to holdingsHoldings up 15%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +31.7%, 3m +60.7%, 6m +41.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-087410, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 13, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +293,601 | $5.91 | $1.7M | 7,058,066 | Sep 4, 2025 |
| Aug 14, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +70,414 | $5.99 | $422k | 7,128,480 | Sep 4, 2025 |
| Aug 15, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +8,233 | $6.00 | $49k | 7,136,713 | Sep 4, 2025 |
| Aug 20, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +71,107 | $5.86 | $416k | 7,207,820 | Sep 4, 2025 |
| Aug 21, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +48,172 | $5.96 | $287k | 7,255,992 | Sep 4, 2025 |
| Aug 22, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +59,788 | $5.96 | $357k | 7,315,780 | Sep 4, 2025 |
| Aug 25, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +338,265 | $6.00 | $2.0M | 7,654,045 | Sep 4, 2025 |
| Aug 26, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +59,648 | $6.00 | $358k | 7,713,693 | Sep 4, 2025 |
| Aug 27, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +50,772 | $6.00 | $305k | 7,764,465 | Sep 4, 2025 |
Related signals
Other insiders at DiaMedica Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | DMACbuy DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $7.6M 1,061,277 shares | +14% | |
| 57Moderate | DiaMedica Therapeutics Inc. | Thomas Von Koch owner | $10.0M 2,857,142 shares | +52% | |
| 53Moderate | DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $5.4M 1,542,857 shares | +30% | |
| 50Moderate | DiaMedica Therapeutics Inc. | Richard Jacinto II owner | $1.4M 400,000 shares | +9% | |
| 30Weak | DMACbuy DiaMedica Therapeutics Inc. | David J. Wambeke Chief Business Officer | $49k 20,000 shares | +4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.